addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please substitute the following claim 1 for the pending claim 1:

1. (Once amended) A compound having the Formula ***I***:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is one of O, S, NR_9, or CH_2, where R_9 is hydrogen or C_1-C_{10} alkyl;

Het is a heteroaryl selected from the group consisting of



(i)



(ii)



(iii)



(iv)

R_1 is selected from the group consisting of hydrogen, optionally substituted alkyl, heteroaryl optionally substituted with one or more groups independently selected from the group consisting of halo, halo(C_{1-6})alkyl, hydroxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro, C_{1-6} alkyl, C_{1-6} alkoxy, aminocarbonyl, carbamoyloxy, C_{1-6} alkylsulfonylamino, C_{1-6} acyl and amino, $C(O)R_{10}$, $CH_2C(O)R_{10}$, $S(O)R_{10}$, and SO_2R_{10};

R_2 and R_3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cyano, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthio,

alkylsulfinyl, alkylsulfonyl, carboxyalkyl, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, alkylcarbonyl, aminosulfonyl, alkylaminosulfonyl, and alkylsulfonyl;

R_5, R_6, R_7, and R_8 are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamino, amide, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R_{10} is selected from the group consisting of amino, alkyl, alkenyl, alkynyl, OR_{11}, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, aralkyl, arylalkenyl, arylalkynyl, and cycloalkylalkylamino;

R_{11} is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkalimetal; and

provided that:

1) when Het is (ii), and X is O, then R_{10} is not alkyl, aralkyl, aryl or OR_{11};
2) when Het is (i) or (ii), then X is not NR_9;
3) when Het is (iii), then X is not CH_2; and
4) when Het is (iii), and X is O, then R_{10} is not OR_{11}.

Please substitute the following claim 10 for the pending claim 10:

10. (Once Amended) A compound of claim 9, wherein:

R_5 and R_6 are each hydrogen;

R_3 and R_2 are both H; and

R_7 and R_8 are selected from the group consisting of hydrogen, halo, halo(C_1-C_6)alkyl, C_1-C_6 alkyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, carboxy(C_1-C_6)alkyl, alkoxy(C_1-C_6)alkyl, nitro, amino, C_1-C_6 acylamino, amide, hydroxy, thiol, C_1-C_6 acyloxy, C_1-C_6 alkoxy, carboxy, carbonylamido and C_1-C_6 alkylthiol.

Please substitute the following claim 15 for the pending claim 15:

15. (Once Amended) A compound of claim 1, wherein:

Het is (i), (ii), (iii) or (iv);

R_1 is $C(O)R_{10}$, $CH_2C(O)R_{10}$, or SO_2R_{10};

X is O or S;

R_{10} is amino, optionally substituted C_1-C_6 alkyl, or a heterocycle selected from the group consisting of N-morpholinyl, N-pyrrolidinyl and N-piperazinyl;

R_2, and R_3 are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylthio or C_1-C_6 alkylsulfinyl,

R_5 and R_6 are as defined in claim 1, and

R_7 and R_8 are independently selected from the group consisting of hydrogen, halo, halo(C_1-C_6)alkyl, C_1-C_6 alkyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, carboxy(C_1-C_6)alkyl, alkoxy(C_1-C_6)alkyl, nitro, amino, C_1-C_6 acylamino, amide, hydroxy, thiol, C_1-C_6 acyloxy, C_1-C_6 alkoxy, carboxy, carbonylamido and C_1-C_6 alkylthiol.

Please substitute the following claim 16 for the pending claim 16:

16. (Once Amended) A compound of Formula *I*:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is O or S;

Het is a heteroaryl selected from the group consisting of



(i)



(ii)



(iii)



(iv)

R_1 is $C(O)R_{10}$, $CH_2C(O)R_{10}$, or SO_2R_{10} wherein R_{10} is amino, alkyl, N-morpholinyl, N-pyrrolidinyl or N-piperazinyl, all of which are optionally substituted;

R_2 and R_3 are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylthio or C_1-C_6 alkylsulfinyl;

R_5, R_6, R_7 and R_8 are independently selected from the group consisting of hydrogen, halo, halo(C_1-C_6)alkyl, C_1-C_6 alkyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl, carboxy(C_1-C_6)alkyl, alkoxy(C_1-C_6)alkyl, nitro, amino, C_1-C_6 acylamino, amide, hydroxy, thiol, C_1-C_6 acyloxy, C_1-C_6 alkoxy, carboxy, carbonylamido and C_1-C_6 alkylthiol;

provided that:

1) when Het is (ii), and X is O, then R_{10} is not alkyl, aralkyl, aryl or OR_{11}; and
2) when Het is (iii), and X is O, then R_{10} is not OR_{11}.

Please substitute the following claim 22 for the pending claim 22:

22. (Once Amended) A compound of Formula *I*:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is O or S;

Het is a heteroaryl selected from the group consisting of



(i)



(ii)



(iii)



(iv)

R_1 is $C(O)R_{10}$, wherein R_{10} is amino, N-morpholinyl, N-pyrrolidinyl or N-piperazinyl, all of which are optionally substituted

R_2 and R_3 are independently hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylthio or C_1-C_6 alkylsulfinyl;

R_5, R_6, R_7 and R_8 are independently selected from the group consisting of hydrogen, halo, halo(C_1-C_6)alkyl, C_1-C_6 alkyl, hydroxy(C_1-C_6)alkyl, amino(C_1-C_6)alkyl,

carboxy(C_1-C_6)alkyl, alkoxy(C_1-C_6)alkyl, nitro, amino, C_1-C_6 acylamino, amide, hydroxy, thiol, C_1-C_6 acyloxy, C_1-C_6 alkoxy, carboxy, carbonylamido and C_1-C_6 alkylthiol.

Please insert the following claims 24-27:

24. (New) A compound of claim 15, wherein R_5 and R_6 are both hydrogen.

25. (New) A compound having the Formula *I*:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is $NR_9C(O)$ or $C(O)NR_9$, where R_9 is hydrogen or C_1-C_{10} alkyl;

Het is a heteroaryl selected from the group consisting of



R_1 is SO_2R_{10};

R_2 and R_3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cyano, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxyalkyl, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, alkylcarbonyl, aminosulfonyl, alkylaminosulfonyl, and alkylsulfonyl;

R_5, R_6, R_7, and R_8 are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamino, amide, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R_{10} is selected from the group consisting of amino, alkyl, alkenyl, alkynyl, OR_{11}, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, aralkyl, arylalkenyl, arylalkynyl, and cycloalkylalkylamino; and

R_{11} is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkalimetal.

26. (New) A compound having the Formula *I*:



I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is one of O, S, NR_9, CH_2, $NR_9C(O)$, or $C(O)NR_9$, where R_9 is hydrogen or C_1-C_{10} alkyl;

Het is a heteroaryl selected from the group consisting of



R_1 is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted heteroaryl, $C(O)R_{10}$, $CH_2C(O)R_{10}$, $S(O)R_{10}$, and SO_2R_{10};

R_2 and R_3 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cyano, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, carboxyalkyl, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aralkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, alkylcarbonyl, aminosulfonyl,

alkylaminosulfonyl, and alkylsulfonyl;

R_5, R_6, R_7, and R_8 are independently selected from the group consisting of hydrogen, halo, haloalkyl, alkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, alkoxyalkyl, nitro, amino, ureido, cyano, acylamino, amide, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, carbonylamido and alkylthiol;

R_{10} is selected from the group consisting of amino, alkyl, alkenyl, alkynyl, OR_{11}, alkylamino, dialkylamino, alkenylamino, dialkylaminoalkenyl, cycloalkyl, heterocycle, heteroaryl, aryl, aralkyl, arylalkenyl, arylalkynyl, and cycloalkylalkylamino;

R_{11} is selected from the group consisting of hydrogen, optionally substituted alkyl, and an alkalimetal; and

wherein said compound is ^{3}H or ^{14}C radiolabeled.

27. (New) The method according to claim 19, wherein the method is for treating, preventing or ameliorating neuronal loss following global or focal ischemia, treating or ameliorating neurodegenerative conditions, treating, preventing or ameliorating pain or tinnitus, treating, preventing or ameliorating manic depression, providing local anesthesia, treating arrhytmias, or treating convulsions.